# A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

> **NCT06691113** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 66 (actual)

## Conditions studied

- Chronic Rhinosinusitis Without Nasal Polyps

## Interventions

- **DRUG:** Itepekimab (SAR440340)
- **DRUG:** Placebo
- **DRUG:** Mometasone furoate nasal spray (MFNS)

## Key facts

- **NCT ID:** NCT06691113
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-08-18
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06691113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06691113, "A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06691113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*